Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 17 Publications

5 Customer Reviews

  • (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm5UZRpUUN3ME21Mlg3PjZizszN M4LUeXNCVkeHUh?=
DOHH-2 M3SzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTlwM{W2PFkh|ryP MoqwV2FPT0WU
no-10 NULT[IVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLV[VVKSzVyPUmuPVA{QSEQvF2= MmroV2FPT0WU
LS-513 M{fp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFzLkO1OFch|ryP MUjTRW5ITVJ?
ALL-PO MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnpTWM2OD1zMT63O|M1KM7:TR?= M321eXNCVkeHUh?=
8-MG-BA Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF|LkGxNlMh|ryP MXHTRW5ITVJ?
RPMI-8402 NXPrNnlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;ndFVxUUN3ME2xOU45PTN5IN88US=> M1rqTnNCVkeHUh?=
EoL-1-cell NWPz[YgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H0WGlEPTB;MUiuOVk1QCEQvF2= MkfqV2FPT0WU
NALM-6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTsc|dKSzVyPUG5MlAyPjdizszN MonGV2FPT0WU
DEL NELONYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorsTWM2OD1{MD6xOFcyKM7:TR?= M1zYbHNCVkeHUh?=
SR MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJ|Lk[3NVUh|ryP NF\rPJVUSU6JRWK=
697 NF3KO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGixRppKSzVyPUK2MlYyPTVizszN NHjV[pdUSU6JRWK=
COLO-829 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXxTWM2OD1{Nj64OFg{KM7:TR?= MkXHV2FPT0WU
EVSA-T MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHNTWM2OD1{Nz61OVYyKM7:TR?= M3:3d3NCVkeHUh?=
ATN-1 NH34R4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTNzLkKzNlkh|ryP MWTTRW5ITVJ?
L-363 NXTDOpJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNzLke0OlEh|ryP MWrTRW5ITVJ?
LAMA-84 M2f1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTN{LkWyNVEh|ryP NVXv[YpXW0GQR1XS
NOS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfncJhKSzVyPUO0MlI6PTZizszN NV;KblBSW0GQR1XS
BB30-HNC NX\1VVVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ezVGlEPTB;M{SuN|MxPiEQvF2= MXPTRW5ITVJ?
BC-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm4TWM2OD1|Nz65O|Q3KM7:TR?= NW\1W4VrW0GQR1XS
IST-SL2 MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz4TWM2OD1|OD6yNlQh|ryP M2XsTXNCVkeHUh?=
D-392MG NHPT[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTRyLkKyNVUh|ryP MUnTRW5ITVJ?
no-11 M2HnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTRyLkW1NlEh|ryP NXXsd2pGW0GQR1XS
LC4-1 M4DtU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;mdWlEPTB;NECuPFcyPiEQvF2= MmfVV2FPT0WU
A388 NHvMbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXsTWM2OD12Mj61PFQ5KM7:TR?= M{jGb3NCVkeHUh?=
NTERA-S-cl-D1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vzWWlEPTB;NEKuO|A4PCEQvF2= MmnDV2FPT0WU
CESS MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\QTWM2OD12ND6yNlMzKM7:TR?= MWLTRW5ITVJ?
RS4-11 NHXYemVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\DOpZKSzVyPUS5MlA6OzhizszN MXvTRW5ITVJ?
MS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVznVnlzUUN3ME21NE46OzVzIN88US=> MYjTRW5ITVJ?
CTV-1 NFjvZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTVzLkC3OEDPxE1? MWTTRW5ITVJ?
D-502MG Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfafHhSUUN3ME21NU43OjdzIN88US=> Mlq4V2FPT0WU
ML-2 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TsV2lEPTB;NUKuPVE6PSEQvF2= NFfuUYhUSU6JRWK=
SK-NEP-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHmXYtKSzVyPUWzMlM6OjNizszN MmfpV2FPT0WU
LOXIMVI M1GyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzLRYd2UUN3ME21N{42QDh2IN88US=> M3[3OXNCVkeHUh?=
DJM-1 M2Lqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTV4LkOzPVEh|ryP MYnTRW5ITVJ?
GI-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfoPZFKSzVyPUW2MlYyPDlizszN M1fuS3NCVkeHUh?=
IST-MES1 M2XxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHDWXFKSzVyPU[wMlU1QTNizszN MnLsV2FPT0WU
MV-4-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTZyLk[1N|gh|ryP M1rLVHNCVkeHUh?=
OVCAR-4 NWL2ZnJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnPTWM2OD14Mz61OlU4KM7:TR?= M4fMenNCVkeHUh?=
KE-37 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTTTWM2OD14Nj6yOlY5KM7:TR?= MorvV2FPT0WU
D-542MG NHHvbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLXW5FWUUN3ME22PE41OTN3IN88US=> NIS3XJZUSU6JRWK=
MHH-PREB-1 NGHJOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\pXlM5UUN3ME23Nk45PDRzIN88US=> NUDVcnpUW0GQR1XS
MRK-nu-1 NYS4Rmg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3uwZmlEPTB;N{OuOFcxPSEQvF2= NETsPYlUSU6JRWK=
D-247MG M3KybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvBTWM2OD15Mz61OFQzKM7:TR?= MYXTRW5ITVJ?
OCI-AML2 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTd4LkmzOlkh|ryP MYjTRW5ITVJ?
LP-1 NXTrdJZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTh{Lki3N|Eh|ryP NHTHfmNUSU6JRWK=
HCC1599 Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHETWM2OD16ND6yPFM4KM7:TR?= MXjTRW5ITVJ?
KARPAS-45 NXrKNJV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTh2Lk[5PVIh|ryP M{fNZXNCVkeHUh?=
BE-13 NITNUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfGU|RKSzVyPUm5MlA1PzdizszN NI\LOnhUSU6JRWK=
GCIY NWXnZ4trT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTl7LkC5OVQh|ryP NF\4UXNUSU6JRWK=
BV-173 MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjCPWVKSzVyPUGwNE4{OjVizszN M3qzXXNCVkeHUh?=
LB2518-MEL M1L0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nYW2lEPTB;MUCwMlc5QSEQvF2= MnjlV2FPT0WU
KS-1 NYnTSJl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjHTWM2OD1zMEGuOlM6KM7:TR?= NYjXUZRTW0GQR1XS
MOLT-16 MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFyND65PFYh|ryP M{fI[HNCVkeHUh?=
NCI-H1770 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLXTWM2OD1zMEiuO|g1KM7:TR?= MWrTRW5ITVJ?
NCI-H82 NEPiSINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f0d2lEPTB;MUGwMlk4PiEQvF2= Mo\XV2FPT0WU
NCCIT MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrURlFKSzVyPUGxNk42OjlizszN MVLTRW5ITVJ?
KALS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vPVmlEPTB;MUG1Mlk1OSEQvF2= NFrQUodUSU6JRWK=
LB2241-RCC NWPUUXdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFzNj62O|kh|ryP NUXCWYlNW0GQR1XS
HH Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2myZWlEPTB;MUG3MlM6PSEQvF2= Mlm2V2FPT0WU
HD-MY-Z M{TjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTxTWM2OD1zMUiuOFg5KM7:TR?= MljTV2FPT0WU
EB-3 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7iXZk1UUN3ME2xNlMvODl2IN88US=> MmnxV2FPT0WU
BL-70 M{jPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnUemFKSzVyPUGyN{4yOjdizszN M{fkcHNCVkeHUh?=
K-562 M3PvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\ofHFKSzVyPUGyOk4zPDVizszN Mm[2V2FPT0WU
HT-144 M{\XZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTZS3hKSzVyPUGzN{4yPjRizszN MV7TRW5ITVJ?
PF-382 M{nRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF|ND6zOlEh|ryP Ml3MV2FPT0WU
RPMI-8226 Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;XTWM2OD1zM{WuNFQ2KM7:TR?= M4XKO3NCVkeHUh?=
NCI-H1355 NW\tXo46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:xdot3UUN3ME2xN|UvPTh5IN88US=> NWC2dZI4W0GQR1XS
LXF-289 NFzMN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\Me4E4UUN3ME2xN|kvPzhzIN88US=> M3K4dnNCVkeHUh?=
NCI-H69 NIK4ZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrSZo5KSzVyPUG0Nk46OzJizszN MXvTRW5ITVJ?
SK-MEL-1 NFvWUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHGTWM2OD1zNEeuNVMh|ryP NXPodoFTW0GQR1XS
KARPAS-299 M{nVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPRTWM2OD1zNEmuNVIh|ryP M{DlTXNCVkeHUh?=
GB-1 NWTVeI12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC5T|JKSzVyPUG0PU4{OjJizszN Mlz3V2FPT0WU
CMK MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF2OT61NVUh|ryP M3nBVHNCVkeHUh?=
MPP-89 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrBelR3UUN3ME2xOVYvODN3IN88US=> NWfMbI9nW0GQR1XS
KU812 MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPq[mRKSzVyPUG2NU46ODJizszN M37we3NCVkeHUh?=
REH MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF4Mj6xNlUh|ryP NVLQdZBrW0GQR1XS
NEC8 MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\DRXRKSzVyPUG2OU4xOjZizszN NFKzXZFUSU6JRWK=
KP-N-YS M{e0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF4OD6zPVUh|ryP MWPTRW5ITVJ?
Ramos-2G6-4C10 NYrEU3JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojGTWM2OD1zNkmuPVE2KM7:TR?= MlH5V2FPT0WU
Becker NGm4NIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF5ND6xPEDPxE1? M1fvRnNCVkeHUh?=
LB647-SCLC M1rKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LM[WlEPTB;MUe1Mlg1PSEQvF2= NVvmSpBTW0GQR1XS
LU-139 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUWzeFZyUUN3ME2xO|gvODF7IN88US=> NV;GeXhvW0GQR1XS
QIMR-WIL NXX4dXBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF5OT62OFYh|ryP M4WwXXNCVkeHUh?=
NCI-H1395 NWnmcWJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrDeWpVUUN3ME2xO|kvQTl4IN88US=> NFHWNWVUSU6JRWK=
NOMO-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPxTWM2OD1zOEKuPFUh|ryP MWnTRW5ITVJ?
GI-ME-N NYjkflhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LwZWlEPTB;MUi3Mlk3QSEQvF2= NGS1TIhUSU6JRWK=
KMS-12-PE MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF6OT6yO|Mh|ryP M16yVHNCVkeHUh?=
Daudi NEKxeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;ETWM2OD1zOUGuNVI5KM7:TR?= MVvTRW5ITVJ?
LB996-RCC MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fsdGlEPTB;MUmxMlY6QSEQvF2= NWjJOXRzW0GQR1XS
NCI-H2107 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3JcVRKSzVyPUG5N{44OzlizszN MYfTRW5ITVJ?
SK-PN-DW M1y2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljRTWM2OD1zOUSuO|E6KM7:TR?= NI\TXlZUSU6JRWK=
MC-CAR MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfuXYxKSzVyPUKwNk4zPTNizszN NX3BNXhNW0GQR1XS
SNB75 NE\Zbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rYSmlEPTB;MkKxMlk1KM7:TR?= NFfoZmVUSU6JRWK=
ES4 NXHXPHJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJ{Mz63PFMh|ryP M3PKfHNCVkeHUh?=
KARPAS-422 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHZO2M{UUN3ME2yNlgvOzV{IN88US=> M2HVUnNCVkeHUh?=
NCI-H1648 NFLFbXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXVR2VKSzVyPUKyPU41QDlizszN MXjTRW5ITVJ?
ES6 MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LJXWlEPTB;MkO5MlQ{KM7:TR?= M2CwS3NCVkeHUh?=
KNS-81-FD NV:1[5BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nsfWlEPTB;MkSxMlE6PyEQvF2= Mm\yV2FPT0WU
JAR M{jYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnOVldKSzVyPUK1Ok4zOjVizszN NV7MTWM4W0GQR1XS
NB1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrafXVKSzVyPUK2NE42OTZizszN MnnBV2FPT0WU
D-336MG MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLaWmgyUUN3ME2yOlAvPjl6IN88US=> NXvtSnZ{W0GQR1XS
BC-3 NGfFc2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK1UIFTUUN3ME2yOlUvOTd6IN88US=> M4fQUXNCVkeHUh?=
HCC2218 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHOc4Z5UUN3ME2yOlYvPDF3IN88US=> MYjTRW5ITVJ?
TE-9 M3HDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvX[FNyUUN3ME2yOlYvPjJ5IN88US=> NGTHdWhUSU6JRWK=
LB1047-RCC NX;DXINNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zrfmlEPTB;Mk[2Mlc2OyEQvF2= M3HFZ3NCVkeHUh?=
CTB-1 M{PRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qzdGlEPTB;Mk[5Mlk4OyEQvF2= Mn\TV2FPT0WU
NB7 NH;qdZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHviNYtKSzVyPUK3NUDPxE1? Ml:5V2FPT0WU
ST486 NHnjcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJ5Nz60NVIh|ryP MlrhV2FPT0WU
HCC1187 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7xXHlKSzVyPUK4Nk45OTFizszN NUPMT|BDW0GQR1XS
NCI-SNU-16 M3v2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXBPItPUUN3ME2yPFQvOjR6IN88US=> MXfTRW5ITVJ?
COR-L279 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:1T4pKSzVyPUK5NU42QDRizszN NWLndFVFW0GQR1XS
ES8 NVHmfXJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjk[FA{UUN3ME2yPVQvOTh{IN88US=> M1L2TXNCVkeHUh?=
U-698-M MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPMfGRSUUN3ME2yPVgvOjR|IN88US=> NGHFdY1USU6JRWK=
HEL M4TjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rJXmlEPTB;M{C5MlE1QSEQvF2= NWrSOWZVW0GQR1XS
KINGS-1 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrJTWM2OD1|MUCuOlc1KM7:TR?= M2rxN3NCVkeHUh?=
KY821 NXTQOJl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3aPJBtUUN3ME2zN|YvPTl3IN88US=> NH;iOpZUSU6JRWK=
MZ1-PC NHfCTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:wclhKSzVyPUO0OU43OThizszN MVzTRW5ITVJ?
LS-411N NX7MNHZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTN3ND62OkDPxE1? MU\TRW5ITVJ?
SIG-M5 Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e5bWlEPTB;M{W5Mlc5OiEQvF2= MYPTRW5ITVJ?
HT NWnNZW54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLSbWF[UUN3ME2zOlcvPzFzIN88US=> MlTuV2FPT0WU
HC-1 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q1fGlEPTB;M{[3Mlc5PyEQvF2= NHzvO2ZUSU6JRWK=
NCI-H1694 NHq0S2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTN5Mj65N|Qh|ryP MXHTRW5ITVJ?
BB65-RCC NWjBUlJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7ZWGZKSzVyPUO3Ok4zPDVizszN MkjQV2FPT0WU
HAL-01 NFTldYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvqbWRKSzVyPUO3PU45OzhizszN MYfTRW5ITVJ?
ARH-77 NFHmO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\NTWM2OD1|OUSuNFA5KM7:TR?= MmLGV2FPT0WU
MZ7-mel M3HpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zBWWlEPTB;M{m3MlI{OyEQvF2= MkT6V2FPT0WU
SIMA NXPGfGFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfYUFJKSzVyPUSwN{46OzNizszN NUfu[HlvW0GQR1XS
DG-75 NWjSS|d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\HUWlEPTB;NEG1MlY6QCEQvF2= NEGwcYVUSU6JRWK=
HUTU-80 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTRzOT6xPFUh|ryP MW\TRW5ITVJ?
KNS-42 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTR{NT64NVUh|ryP Mn31V2FPT0WU
SH-4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHXTWM2OD12MkeuOVY2KM7:TR?= M3\SUHNCVkeHUh?=
L-540 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTR|MT6wN|Eh|ryP M13LNHNCVkeHUh?=
NB10 NFvSO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnlfXh[UUN3ME20OFEvOjN2IN88US=> NI[xcIdUSU6JRWK=
ES1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj2UVBKSzVyPUS1Nk44PTNizszN NWfDZWlwW0GQR1XS
KMOE-2 NXflRlZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTR3Nj63NVEh|ryP NGTTb|lUSU6JRWK=
MC116 MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TqcmlEPTB;NEW4MlEyPiEQvF2= MXPTRW5ITVJ?
RCC10RGB NISwUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TqO2lEPTB;NE[wMlAxPSEQvF2= MkfqV2FPT0WU
RL95-2 NXrGUWpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLzTWM2OD12NkCuNlM4KM7:TR?= MXjTRW5ITVJ?
Raji MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTDTWM2OD12NkiuNVQ{KM7:TR?= M1LzWHNCVkeHUh?=
CAS-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n6TGlEPTB;NEeyMlA4OyEQvF2= M1\P[nNCVkeHUh?=
Calu-6 NXjZ[VJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlftTWM2OD12N{WuNlY2KM7:TR?= MWfTRW5ITVJ?
KG-1 NEDZWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe0Z49lUUN3ME20O|gvPDRizszN MnrBV2FPT0WU
LB771-HNC MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j6b2lEPTB;NEiyMlI{OiEQvF2= Mnn3V2FPT0WU
ACN Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M363eGlEPTB;NEmzMlU6QSEQvF2= NEnKeYpUSU6JRWK=
KM12 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT2TWM2OD12OU[uOVg6KM7:TR?= NYjQXoQ{W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products4

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID